1390. Durlobactam, a Diazabicyclooctane (DBO) β-lactamase Inhibitor (BLI), Inhibits BlaC and Peptidoglycan (PG) Transpeptidases of Mycobacterium tuberculosis (Mtb): A Novel Approach to Therapeutics for Tuberculosis (TB)?
In: Open Forum Infect Dis, 2021
academicJournal
Zugriff:
BACKGROUND: Novel therapies for multidrug-resistant TB are needed and new BLIs could answer this call. Mtb encodes for BlaC, a class A β-lactamase. BlaC is inhibited by clavulanate (CLA) while the DBO avibactam (AVI) is an inefficient inhibitor (low k(2)/K value). Carbapenems are hydrolyzed slowly by BlaC (low k(cat)/K(m) value) making them “dual action” compounds that inhibit both BlaC and PG transpeptidases, the intended β-lactam targets. DBOs inhibit PG transpeptidases in other bacteria. To explore the therapeutic potential of new DBOs against Mtb, we compared the inhibitor activity of AVI, relebactam (REL), and durlobactam (DUR, formerly ETX2514) against BlaC and Mtb PG transpeptidases using a biochemical approach. We also investigated the ability of DUR to lower minimum inhibitory concentrations (MICs) of β-lactams against Mtb H37Rv. METHODS: Mass spectrometry was performed to capture acyl-enzyme complexes (AECs) of purified BlaC and PG transpeptidases (PonA1, Ldt(Mt1), Ldt(Mt2,) Ldt(Mt3), and Ldt(Mt5)) with β-lactams and BLIs. Steady-state enzyme kinetics were determined using nitrocefin as a substrate. MICs with amoxicillin (AMX), meropenem (MER), CLA, and DUR alone and in combination against Mtb H37Rv were assessed using a microdilution method. RESULTS: DUR alone had a MIC of 2 µg/mL with Mtb H37Rv (Table 1). BlaC formed AECs with all carbapenems and BLIs. BlaC had lower K(i app) and higher k(2)/K with DUR than those with AVI and REL and comparable to those with CLA; however, with a period of pre-incubation, AVI fully inhibits BlaC (Table 2). The carbapenems and DUR formed the most AECs with PG transpeptidases of the β-lactams and BLIs respectively; PG transpeptidases had lower K(i app) values with DUR than those with AVI (Table 3). Table 1. Minimum Inhibitory Concetrations for Mycobacterium tuberculosis H37Rv [Image: see text] [Image: see text] [Image: see text] CONCLUSION: DUR alone has some antimicrobial activity against Mtb H37Rv. The likely mechanism that underlies this activity is inhibition of ...
Titel: |
1390. Durlobactam, a Diazabicyclooctane (DBO) β-lactamase Inhibitor (BLI), Inhibits BlaC and Peptidoglycan (PG) Transpeptidases of Mycobacterium tuberculosis (Mtb): A Novel Approach to Therapeutics for Tuberculosis (TB)?
|
---|---|
Autor/in / Beteiligte Person: | Nguyen, David ; Bethel, Christopher ; Taracilla, Magdalena A ; Li, Qing ; Dousa, Khalid M ; Kurz, Sebastian G ; Nguyen, Liem ; Kreiswirth, Barry N ; Boom, Wilem ; Bonomo, Robert A |
Link: | |
Zeitschrift: | Open Forum Infect Dis, 2021 |
Veröffentlichung: | Oxford University Press, 2021 |
Medientyp: | academicJournal |
DOI: | 10.1093/ofid/ofab466.1582 |
Schlagwort: |
|
Sonstiges: |
|